The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...

The prospect of Lundbeck and Otsuka’s Rexulti becoming part of a new treatment for post-traumatic stress disorder (PTSD) ...

Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...

Glofitamab is a bispecific CD20-directed CD3 T-cell engager approved under the brand name Columvi ® for the treatment of adults with R/R DLBCL, not otherwise specified or large B-cell lymphoma arising ...

Mushrooms sold across two states have been recalled over fears they could be harboring listeria, a bug that "can cause serious and sometimes fatal infections." ...

Kilwins Quality Confections, LLC. issued a voluntary recall for Mocha Truffles products due to possible undeclared pecans.

Hinge Health's strong partnerships, high client retention, and integration with major health plans drive predictable revenue and market expansion. Learn more on HNGE stock here.

ImmunityBio sees bullish momentum from ASCO data and UK approval for ANKTIVA, despite FDA and cash risks. Check out why IBRX stock is a buy.

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.